Skip to content
BillRazor
Generic J1652 · Anticoagulants

FONDAPARINUX 2.5 MG/0.5 ML SYR

Fondaparinux 2.5 mg/0.5 ml syringes have a Medicare acquisition cost of $28.11, though hospitals typically charge 8-15 times this amount for the same anticoagulant medication.

By Michael Glenn , Healthcare Data Analyst · ·
Data from CMS files published FY 2024 CMS IPPS. Refreshed weekly.
About the analyst

Michael Glenn reviews CMS datasets and drug pricing at BillRazor Research. He focuses on NADAC acquisition costs and procedure coding accuracy. Expertise: drug pricing, NADAC data, CPT coding.

NADAC acquisition cost data
CMS drug pricing benchmarks
Updated 2026-04-03
Drug acquisition cost — FONDAPARINUX 2.5 MG/0.5 ML SYR
NADAC cost$28.11 per unit
Hospital charges for this drug vary — typically 3–8x the acquisition cost. No observed hospital charge data is available for this specific drug.
$28.11
NADAC acquisition cost
SOLUTION
Dosage form
SUBCUTANEOUS
Route

Fondaparinux is an anticoagulant injection used to prevent blood clots, typically administered in hospital or outpatient settings following surgery or for certain medical conditions. This medication often requires prior authorization from insurers and may have significant cost variations between different healthcare facilities.

Check your bill amount
Enter the charge for FONDAPARINUX 2.5 MG/0.5 ML SYR from your bill to compare against the NADAC acquisition cost.
$

No credit card required. Results in 60 seconds.

Research suggests 49–80% of hospital bills contain errors. Our system checks every line item against Medicare benchmarks.

Common billing errors — Anticoagulants charges

Anticoagulant billing presents several recurring issues for hospital patients. Generic substitution errors frequently occur when hospitals bill for brand-name warfarin or enoxaparin while dispensing generic equivalents, creating potential differences of 200-400% above acquisition costs. Duplicate billing commonly appears when patients receive both oral and injectable anticoagulants during transitions, with charges for overlapping days appearing on the same statement. Hospital markups on this drug class typically range from 300-800% above the average NADAC benchmark of $18.84, with some institutions charging $150-200 for medications with acquisition costs under $25. Dosing consolidation errors also create billing discrepancies when multiple small-dose administrations are billed separately instead of as combined therapeutic doses, particularly with heparin protocols. Patients should verify that billed quantities match actual administration records and confirm whether generic or brand medications were dispensed, as charges above benchmark pricing are most pronounced in this therapeutic category due to frequent hospital inventory practices.

What to check on your bill

When reviewing anticoagulant charges on your hospital bill, examine the pharmacy section for specific drug names like warfarin, heparin, enoxaparin (Lovenox), or rivaroxaban (Xarelto). Check for duplicate entries across different billing days, as anticoagulants are often administered multiple times daily. Look for charges listed under both "pharmacy" and "medical supplies" sections, which may indicate double billing for the same medication. Verify dosage amounts match your medical records, as anticoagulant doses vary significantly by patient weight and condition. Review any charges above the benchmark for brand-name anticoagulants when generic equivalents were administered. Pay attention to administration fees listed separately from the drug cost itself, particularly for injectable anticoagulants like heparin. Compare daily anticoagulant charges for consistency, as unexplained variations may indicate billing errors. Check if charges for monitoring tests like PT/INR or anti-Xa levels appear under laboratory services, as these are separate from the medication costs and should not be bundled with drug charges.

Rates shown are from the 2026 Medicare Physician Fee Schedule and CMS IPPS. BillRazor compares your bill against these data sources. See how it works →

FAQ — Anticoagulants billing

What is the average acquisition cost for anticoagulant drugs?
The average NADAC acquisition cost for anticoagulant drugs is $18.84. This benchmark represents the average price that pharmacies pay to acquire these medications from wholesalers or manufacturers.
How many drugs are included in the anticoagulant class for billing analysis?
There are 8 drugs classified in the anticoagulant category for billing purposes. This class includes various medications used to prevent blood clotting, each with different acquisition costs and billing considerations.
How can I identify charges above the benchmark for anticoagulant medications?
Compare your billed amounts against the $18.84 average NADAC acquisition cost for anticoagulants. Any charges significantly above this benchmark may warrant further review of your billing records and contracts with pharmaceutical suppliers.
What should I consider when reviewing anticoagulant drug billing?
Review each of the 8 anticoagulant drugs individually, as costs can vary significantly within the class. The $18.84 average provides a baseline, but individual drug acquisition costs may show substantial potential differences from this benchmark amount.

Related pricing data

Data source: National Average Drug Acquisition Cost (NADAC) survey, published by CMS. HCPCS drug pricing codes from Medicare Part B Drug Average Sales Price file.

What NADAC means: The average price pharmacies pay to acquire this drug from wholesalers. Hospital charges for the same drug are typically higher due to facility fees, compounding, and administration costs.

Limitations: NADAC reflects pharmacy acquisition cost, not patient out-of-pocket cost. Insurance copays, formulary tiers, and manufacturer rebates affect what patients actually pay.

Upload your bill — free instant analysis